Journals / Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi / 2022 / Cilt: 9 - Sayı: 1

A Rare Disease: X-Linked Childhood Cerebral Adrenoleukodystrophy and Nursing Care

Nadir Bir Hastalık: X’e Bağlı Çocukluk Çağı Serebral Adrenolökodistrofisi ve Hemşirelik Bakımı

Pages
74–81
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Quality care provided to these patients who need full-time nursing care can significantly improve their quality of life.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The cerebral childhood form of X-linked Adrenoleukodystrophy is a rare peroxisomal disease with progressive neurodegenerative symptoms affecting the brain's white matter and the adrenal cortex.
📊
Key Findings & Data:This disease, which is not seen before the age of 2.5, begins to show its initial symptoms between 4-10 when demyelination peaks.
💡
Conclusion & Impact:Quality care provided to these patients who need full-time nursing care can significantly improve their quality of life.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hastalık · hemşirelik · kalıtım

Abstract

The cerebral childhood form of X-linked Adrenoleukodystrophy is a rare peroxisomal disease with progressive neurodegenerative symptoms affecting the brain's white matter and the adrenal cortex. This disease, which is not seen before the age of 2.5, begins to show its initial symptoms between 4-10 when demyelination peaks. Initially, nonspecific symptoms make diagnosis difficult. Definitive diagnosis is made by determining the mutation in the ABCD1 gene by molecular genetic testing. It is a disease that can be treated with hematopoietic stem cell transplantation in patients without severe neurological dysfunction. Alternative nutrition strategies, primarily Lorenzo's oil, have been developed to slow the progression of neurological degeneration. Quality care provided to these patients who need full-time nursing care can significantly improve their quality of life.

Özet

X’e bağlı Adrenolökodistrofi’nin çocukluk çağı serebral formu beynin beyaz cevher tabakasını ve adrenal korteksi etkileyen, ilerleyici nörodejeneratif semptomları olan nadir peroksizomal bir hastalıktır. 2.5 yaşından önce görülmeyen bu hastalık demiyelinizasyonun zirveye çıktığı 4-10 yaş arasında başlangıç semptomlarını vermeye başlar. Başlangıçta spesifik olmayan semptomlar tanı konulmasını zorlaştırır. Moleküler genetik test ile ABCD1 genindeki mutasyonun belirlenmesi ile kesin tanı konulur. Ciddi nörolojik disfonksiyonu olmayan hastalarda hematopoetik kök hücre nakli ile tedavi edilebilen bir hastalıktır. Nörolojik dejenerasyonun ilerlemesini yavaşlatmada başta Lorenzo yağı olmak üzere alternatif beslenme stratejileri geliştirilmiştir. Tam zamanlı hemşirelik bakımına ihtiyaç duyan bu hastalara verilen kaliteli bir bakım hastaların yaşam kaliteleri önemli ölçüde arttırılabilir.

🔖

Cite This Article

AKCAN, G. Ö., GÜNEY, R. (2022). A Rare Disease: X-Linked Childhood Cerebral Adrenoleukodystrophy and Nursing Care. Hacettepe Üniversitesi Hemşirelik Fakültesi Dergisi, Cilt: 9 - Sayı: 1, 74–81. https://ajindex.com/articles/532625

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Engelen M, Kemp S, De Visser M, Van Geel BM, Wanders RJA, Aubourg P, et al. X-linked adrenoleukodystrophy (X-ALD): Clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet Journalof Rare Diseases. 2012;7:51-65
  2. Kato K, Maemura R, Wakamatsu M, Yamamoria A, Hamadaa M, Kataoka S, et al. Allogenic stem cell transplantation with reduced intensity conditioning for patients with adrenoleukodystrophy. Moleculer Genetics and Metabolism Reports. 2019;18:1-6
  3. Benjellun FMZ, Kriouile Y, Cheillan D, Daoud-Tetouani H, Chabraoui L. Management of X-linked adrenoleukodystrophy in Morocco: actual situation. BMC Res Notes. 2017;10:567
  4. Raymond GV, Moser AB, Fatemi A. X-Linked adrenoleukodystrophy. Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews. Seattle (WA): University of Washington; 2018
  5. Türkiye Halk Sağlığı ve Kronik Hastalıklar Enstitüsü. Nadir hastalıklar raporu [İnternet]. 2019 [Erişim Tarihi 14.01.2020]. Erişim adresi:
  6. Furlan FLS, Lemes, MA, Suguimatsu, LCF, Pires, CTF, Santos, MLSF. X-Linked adrenoleukodystrophy ın Brazıl: A Case Series. Rev Paul Pediatr. 2019;37(4):465-71
  7. Maertens P. Inborn errors of metabolizm ı: neurologic degenerative diseases. David RB, Bodensteiner JB, Mandelbaum, DE, Olson B, editors. Clinical Pediatric Neurology. 3rd ed. USA: Demos Medical; 2009
  8. Botelho E, Bothelho E, Rodrigues L, Wanderley T, Queiroz F, Borgeset P et al. Adrenal ınsufficiency by adrenoleukodystrophy. Health. 2020;12:1-13
  9. Orchard PJ, Nascene DR, Miller WP, Gupta A, Kenney-Jung D, Lund TC. Successful donor engraftment and repair of the blood-brain barrier in cerebral adrenoleukodystrophy. Blood. 2019;133(12):1378-81
  10. National Organization for Rare Disorders. X-Linked adrenoleukodystrophy [İnternet]. 2019 [Erişim Tarihi 14.01.2020]. Erişim adresi:
  11. Moser HW. Therapy of X- linked adrenoleukodystrophy. The American Society for Experimental NeuroTherapeutics. 2006; 3:246 –53
  12. ALD info. The information platform to all aspects of adrenoleukodystrophy and the worldwide registry for ABCD1 mutations [İnternet]. 2019 [Erişim Tarihi 13.01.2020]. Erişim adresi:
  13. Lee S, Clinard K, Young SP, Rehder CW, Fan Z, Calikoglu AS, et al. Evaluation of X-linked adrenoleukodystrophy newborn screening in North Carolina. JAMA Netw